Terms: = Prostate cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Clinical Outcome
2 results:
1. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant prostate cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract] [Full Text] [Related]
2. TEAD1 and c-cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
Knight JF; Shepherd CJ; Rizzo S; Brewer D; Jhavar S; Dodson AR; Cooper CS; Eeles R; Falconer A; Kovacs G; Garrett MD; Norman AR; Shipley J; Hudson DL
Br J Cancer; 2008 Dec; 99(11):1849-58. PubMed ID: 19002168
[TBL] [Abstract] [Full Text] [Related]
